King Rachel K. 4
4 · Fulcrum Therapeutics, Inc. · Filed Jun 30, 2025
Insider Transaction Report
Form 4
King Rachel K.
Director
Transactions
- Award
Stock Option (right to buy)
2025-06-26+36,000→ 36,000 totalExercise: $7.38Exp: 2035-06-25→ Common Stock (36,000 underlying)
Footnotes (1)
- [F1]This option was granted on June 26, 2025 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service.